Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Wilens, T. E. Articles by Polisner, D. Search for Related Content PubMed Citation Articles by Wilens, T. E. Articles by Polisner, D. Attention Deficit Hyperactivity Disorder Other Somatic Therapy

A Pilot Controlled Clinical Trial of ABT-418, a Cholinergic Agonist, in the Treatment of Adults With Attention Deficit Hyperactivity Disorder

OBJECTIVE: Despite the increasing recognition of attention deficit hyperactivity disorder (ADHD) in adults, there is a paucity of controlled pharmacological trials. Recent reports have suggested the potential usefulness of cholinergic agents for ADHD. To this end, the authors completed a controlled study of ABT-418, a novel cholinergic activating agent, for the treatment of adults with ADHD. METHOD: This was a double-blind, placebo-controlled, randomized, crossover trial that compared a transdermal patch of ABT-418 (75 mg/day) to placebo in adults who met DSM-IV criteria for ADHD. There were two 3-week treatment periods separated by 1 week of washout. RESULTS: Of the 32 subjects enrolled in the study (88% were men; mean age=40 years, SD=9), 29 completed the study. At the endpoint of each active arm (last observation carried forward), a significantly higher proportion of subjects was considered improved while receiving ABT-418 than while receiving placebo (40% versus 13%). Similarly, at endpoint there was a significantly greater reduction in ADHD symptom checklist scores (28% versus 15%). Symptoms reflective of attention, and subjects with less severe ADHD, responded more robustly to ABT-418. Treatment with ABT-418 was relatively well tolerated; dizziness and nausea were the most frequently reported adverse effects. CONCLUSIONS: The results of this investigation indicate that ABT-418, a nicotinic analog, may be a potentially useful agent for the treatment of ADHD.

This article has been cited by other articles:

				J. G. Wood, J. L. Crager, C. M. Delap, and K. D. Heiskell Literature Review: Beyond Methylphenidate: Nonstimulant Medications for Youth With ADHD J Atten Disord, November 1, 2007; 11(3): 341 - 350. [Abstract] [PDF]

				G. Dunbar, A. Demazieres, A. Monreal, C. Cisterni, D. Metzger, R. Kuchibhatla, and R. Luthringer Pharmacokinetics and Safety Profile of Ispronicline (TC-1734), a New Brain Nicotinic Receptor Partial Agonist, in Young Healthy Male Volunteers. J. Clin. Pharmacol., July 1, 2006; 46(7): 715 - 726. [Abstract] [Full Text] [PDF]

				T. A. Esbenshade, G. B. Fox, and M. D. Cowart Histamine h3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv., April 1, 2006; 6(2): 77 - 88. [Abstract] [Full Text] [PDF]

				R. L. Doyle, J. Frazier, T. J. Spencer, D. Geller, J. Biederman, and T. Wilens Donepezil in the Treatment of ADHD-Like Symptoms in Youths With Pervasive Developmental Disorder: A Case Series. J Atten Disord, February 1, 2006; 9(3): 543 - 549. [Abstract] [PDF]

				K. A. Sacco, K. L. Bannon, and T. P. George Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders J Psychopharmacol, December 1, 2004; 18(4): 457 - 474. [Abstract] [PDF]

				J. J. McGough and R. A. Barkley Diagnostic Controversies in Adult Attention Deficit Hyperactivity Disorder Am J Psychiatry, November 1, 2004; 161(11): 1948 - 1956. [Abstract] [Full Text] [PDF]

				L. L. Greenhill, S. Pliszka, M. K. Dulcan, W. Bernet, V. Arnold, J. Beitchman, R. S. Benson, O. Bukstein, J. Kinlan, J. McClellan, et al. Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults Focus, October 1, 2004; 2(4): 642 - 668. [Abstract] [Full Text] [PDF]

				D. Coghill Current issues in child and adolescent psychopharmacology. Part 1: Attention-deficit hyperactivity and affective disorders Advan. Psychiatr. Treat., March 1, 2003; 9(2): 86 - 94. [Abstract] [Full Text] [PDF]

				K.-i. Ueno, H. Togashi, M. Matsumoto, S. Ohashi, H. Saito, and M. Yoshioka alpha 4beta 2 Nicotinic Acetylcholine Receptor Activation Ameliorates Impairment of Spontaneous Alternation Behavior in Stroke-Prone Spontaneously Hypertensive Rats, an Animal Model of Attention Deficit Hyperactivity Disorder J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 95 - 100. [Abstract] [Full Text] [PDF]

				T. E. Wilens, T. J. Spencer, and J. Biederman A review of the pharmacotherapy of adults with Attention-Deficit/ Hyperactivity Disorder J Atten Disord, January 1, 2001; 5(4): 189 - 202. [Abstract] [PDF]

				G. K. Lloyd and M. Williams Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 461 - 467. [Full Text]

				Can a Nicotinic Cholinergic Analog Help Patients with ADHD? Journal Watch Psychiatry, January 1, 2000; 2000(101): 3 - 3. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us